These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 1555965)

  • 21. More accurate fitting of 125I and 103Pd radial dose functions.
    Taylor RE; Rogers DW
    Med Phys; 2008 Sep; 35(9):4242-50. PubMed ID: 18841874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measurement of dose-rate constant for 103Pd seeds with air kerma strength calibration based upon a primary national standard.
    Nath R; Yue N; Shahnazi K; Bongiorni PJ
    Med Phys; 2000 Apr; 27(4):655-8. PubMed ID: 10798685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dosimetric effects of needle divergence in prostate seed implant using 125I and 103Pd radioactive seeds.
    Nath S; Chen Z; Yue N; Trumpore S; Peschel R
    Med Phys; 2000 May; 27(5):1058-66. PubMed ID: 10841410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monte Carlo calculations and experimental measurements of dosimetry parameters of a new 103Pd source.
    Li Z; Palta JR; Fan JJ
    Med Phys; 2000 May; 27(5):1108-12. PubMed ID: 10841416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relative biological effectiveness of 103Pd and 125I photons for continuous low-dose-rate irradiation of Chinese hamster cells.
    Nath R; Bongiorni P; Chen Z; Gragnano J; Rockwell S
    Radiat Res; 2005 May; 163(5):501-9. PubMed ID: 15850411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Approaches to calculating AAPM TG-43 brachytherapy dosimetry parameters for 137Cs, 125I, 192Ir, 103Pd, and 169Yb sources.
    Melhus CS; Rivard MJ
    Med Phys; 2006 Jun; 33(6):1729-37. PubMed ID: 16872080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
    Dicker AP; Lin CC; Leeper DB; Waterman FM
    Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Theoretical analysis of microdosimetric spectra and cluster formation for 103Pd and 125I photon emitters.
    Reniers B; Vynckier S; Verhaegen F
    Phys Med Biol; 2004 Aug; 49(16):3781-95. PubMed ID: 15446805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anisotropy functions for 103Pd, 125I, and 192Ir interstitial brachytherapy sources.
    Nath R; Meigooni AS; Muench P; Melillo A
    Med Phys; 1993; 20(5):1465-73. PubMed ID: 8289730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prescription dose in permanent (131)Cs seed prostate implants.
    Yue N; Heron DE; Komanduri K; Huq MS
    Med Phys; 2005 Aug; 32(8):2496-502. PubMed ID: 16193779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A theoretical investigation into the role of tumour radiosensitivity, clonogen repopulation, tumour shrinkage and radionuclide RBE in permanent brachytherapy implants of 125I and 103Pd.
    Antipas V; Dale RG; Coles IP
    Phys Med Biol; 2001 Oct; 46(10):2557-69. PubMed ID: 11686275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Well-ionization chamber response relative to NIST air-kerma strength standard for prostate brachytherapy seeds.
    Mitch MG; Zimmerman BE; Lamperti PJ; Seltzer SM; Coursey BM
    Med Phys; 2000 Oct; 27(10):2293-6. PubMed ID: 11099196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between isotope half-life and prostatic edema for optimal prostate dose coverage in permanent seed implants.
    Villeneuve M; Leclerc G; Lessard E; Pouliot J; Beaulieu L
    Med Phys; 2008 May; 35(5):1970-7. PubMed ID: 18561673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose rate constant and energy spectrum of interstitial brachytherapy sources.
    Chen Z; Nath R
    Med Phys; 2001 Jan; 28(1):86-96. PubMed ID: 11213926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy.
    Thomson RM; Taylor RE; Rogers DW
    Med Phys; 2008 Dec; 35(12):5530-43. PubMed ID: 19175111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose calculation for permanent prostate implants incorporating spatially anisotropic linearly time-resolving edema.
    Monajemi TT; Clements CM; Sloboda RS
    Med Phys; 2011 Apr; 38(4):2289-98. PubMed ID: 21626964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radial dose functions for 103Pd, 125I, 169Yb and 192Ir brachytherapy sources: an EGS4 Monte Carlo study.
    Mainegra E; Capote R; López E
    Phys Med Biol; 2000 Mar; 45(3):703-17. PubMed ID: 10730965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential impact of prostate edema on the dosimetry of permanent seed implants using the new 131Cs (model CS-1) seeds.
    Chen Z; Deng J; Roberts K; Nath R
    Med Phys; 2006 Apr; 33(4):968-75. PubMed ID: 16696473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Technique of intraoperative planning in prostatic brachytherapy with permanent implants of 125I or 103Pd].
    Prada Gómez PJ; Juan Rijo G; Hevia Suarez M; Abascal García JM; Abascal García R
    Arch Esp Urol; 2002 Dec; 55(10):1217-23; discussion 1223-4. PubMed ID: 12611219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calculated microdosimetric characteristics of 125I and 103Pd brachytherapy seeds at different depths in water.
    Wuu CS; Chen J
    Radiat Prot Dosimetry; 2006; 122(1-4):506-8. PubMed ID: 17189276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.